会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 42. 发明公开
    • PROCESS FOR SYNTHESIZING $g(b)-LACTAM
    • VERFAHREN ZUR SYNTHESE VON?-LACTAMEN
    • EP1346981A1
    • 2003-09-24
    • EP01912138.3
    • 2001-03-07
    • National Institute of Advanced Industrial Science and Technology
    • HATAKEDA, KiyotakaSATO, OsamuKANAKUBO, MitsuhiroIKUSHIMA, YutakaTORII, Kazuo
    • C07D201/08C07D205/08
    • C07D201/08Y02P20/582
    • It is an object of the present invention to provide a method for synthesizing β-lactams and a method for manufacturing β-lactams in water of high-temperature and under high-pressure, and the present invention relates to a β-lactam synthesis method which is characterized in that β-lactams are synthesized by reacting β-amino acids in water at high-temperature and under high-pressure, this method being further characterized in that β-lactams are synthesized at a high speed by cyclizing β-amino acids in water at high-temperature and under high-pressure in which the temperature range is 200°C or higher and the pressure range is 10 MPa or greater, and the present invention also relates to a method for manufacturing β-lactams which is characterized in that β-lactams are synthesized by reacting β-amino acids in water at high-temperature and under high-pressure, and are then separated and purified using a column separation medium.
    • 本发明的目的是提供一种合成β-内酰胺的方法和在高温和高压水中制备β-内酰胺的方法,本发明涉及β-内酰胺合成方法 其特征在于通过β-氨基酸在高温和高压下在水中反应来合成β-内酰胺,该方法的进一步特征在于通过使β-氨基酸在高温和高压下环化β-氨基酸来合成β-内酰胺 在温度范围为200℃以上且压力范围为10MPa以上的高温高压下的水,本发明还涉及β-内酰胺的制造方法,其特征在于, β-内酰胺通过在高温和高压下在水中使β-氨基酸反应合成,然后使用柱分离介质分离和纯化。
    • 47. 发明公开
    • Process for the deprotection of N-substituted azetidones
    • Verfahren zumentschützenvon N-substitutionierten Azetidonen
    • EP1256572A1
    • 2002-11-13
    • EP01870100.3
    • 2001-05-10
    • Tessenderlo Chemie S.A.
    • Ceresiat, Marcel Maurice GhislainBelmans, MarcMarchand-Brynaert, JaquelineLaurent, Mathieu
    • C07D205/08
    • C07D205/08Y02P20/55
    • The present invention relates to a method for the preparation of a compound of the general formula (I) wherein

      R 1 and R 2 each represent independently hydrogen, halogen, hydroxy, thiol, nitro, amino, carboxy, amino derivative, oxy derivative, thio derivative, alkyl, alkenyl, alkynyl, aryl, oxy derivative, amino derivative, thiol derivative, acyl derivative, acyloxy derivative, ester, amido, ether, arylalkyl, heterocycle or Me(OR')CH wherein R' is hydrogen or R a R b R c Si wherein R a , R b and R c is independently chosen from the group consisting of alkyl, alkenyl, alkynyl, aryl or a heterocycle;
      R 3 represents a protecting group such as alkyl, alkenyl, alkynyl, or arylalkyl;
      wherein this method comprises the reaction of a compound of the general formula (II) in the presence of a halogen-radical source, water and a proton donor suitable as a catalyst.
    • 本发明涉及制备通式(I)的化合物的方法,其中R 1和R 2各自独立地代表氢,卤素,羟基,硫醇,硝基,氨基,羧基,氨基衍生物, 氧基衍生物,硫代衍生物,烷基,烯基,炔基,芳基,氧基衍生物,氨基衍生物,硫醇衍生物,酰基衍生物,酰氧基衍生物,酯,酰胺基,醚,芳基烷基,杂环或Me(OR')CH,其中R' 或R a R c R c Si,其中R a,R b和R c独立地选自烷基,烯基,炔基,芳基或杂环; R 3表示保护基如烷基,烯基,炔基或芳基烷基; 其中该方法包括通式(II)的化合物在卤素自由基源,水和适合作为催化剂的质子给体存在下的反应。
    • 49. 发明授权
    • SULFUR-SUBSTITUTED AZETIDINONE COMPOUNDS USEFUL AS HYPOCHOLESTEROLEMIC AGENTS
    • 硫取代的AZETDINONE HYPOCHOLESTEROLMISCHMITTEL
    • EP0792264B1
    • 2002-02-27
    • EP95939677.1
    • 1995-11-15
    • SCHERING CORPORATION
    • McKITTRICK, Brian, A.DUGAR, SundeepBURNETT, Duane, A.
    • C07D205/08C07D409/12C07D401/12A61K31/395A61K31/44
    • C07D401/12C07D205/08C07D409/12
    • Sulfur-substituted azetidinone hypocholesterolemic agents of formula (I), or a pharmaceutically acceptable salt thereof, wherein: Ar1 is aryl, R10-substituted aryl or heteroaryl; Ar2 is aryl or R4-substituted aryl; Ar3 is aryl or R5-substituted aryl; X and Y are -CH¿2?-, -CH(lower alkyl)- or -C(dilower alkyl)-; R is -OR?6¿, -O(CO)R6, -O(CO)OR9 or -O(CO)NR6R7; R1 is hydrogen, lower alkyl or aryl; or R and R1 together are =0; q is 0 or 1; r is 0, 1 or 2; m and n are 0-5; provided that the sum of m, n and q is 1-5; R4 is selected from lower alkyl, -OR6, -O(CO)R6, -O(CO)OR9, -O(CH¿2?)1-5OR?6¿, -O(CO)NR?6R7, -NR6R7, -NR6(CO)R7, -NR6(CO)OR9, -NR6(CO)NR7R8, -NR6SO¿2R?9, -COOR6, -CONR6R7, -COR6, -SO¿2NR6R7, S(O)¿0-2R?9, -O(CH¿2?)1-10-COOR?6¿, -O(CH¿2?)1-10CONR?6R7¿, -(lower alkylene)-COOR6 and -CH=CH-COOR6; R5 is selected from -OR6, -O(CO)R6, -O(CO)OR9, -O(CH¿2?)1-5OR?6¿, -O(CO)NR?6R7, -NR6?R?7 -NR6(CO)R7, -NR6(CO)OR9, -NR6(CO)NR7R8, -NR6SO¿2R?9, -COOR6, -CONR6R7, -COR6, -SO¿2NR6R7, S(O)¿0-2R?9, -O(CH¿2?)1-10-COOR?6¿, -O(CH¿2?)1-10CONR?6R7, -CF¿3, -CN, -NO2, halogen, -(lower alkylene)COOR6 and -CH=CH-COOR?6; R6, R7 and R8¿ are H, lower alkyl, aryl or aryl-substitued lower alkyl; R9 is lower alkyl, aryl or aryl-sybstituted lower alkyl; and R10 is selected from lower alkyl, -OR6, -O(CO)R6, -O(CO)OR9, -O(CH¿2?)1-5OR?6¿, -O(CO)NR?6R7, -NR6R7, -NR6(CO)R7, -NR6(CO)OR9, -NR6(CO)NR7R8, -NR6SO¿2R?9, -COOR6, -CONR6R7, COR6, -SO¿2NR6R7, -S(O)¿0-2R?9, -O(CH¿2?)1-10-COOR?6¿, -O(CH¿2?)1-10CONR?6R7, -CF¿3, -CN, -NO2 and halogen; are disclosed, as well as pharmaceutical compositions containing them, and a method of lowering serum cholesterol by administering said compounds, alone or in combination with a cholesterol biosynthesis inhibitor.